| Pair Name | Vinpocetine, Sorafenib | ||
| Phytochemical Name | Vinpocetine (PubChem CID: 443955 ) | ||
| Anticancer drug Name | Sorafenib (PubChem CID: 216239 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Vinpocetine, Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Activity | GSK3B | hsa2932 | |
| Up-regulation | Expression | MAP1LC3A | hsa84557 | |
| Down-regulation | Expression | MCL1 | hsa4170 | |
| Down-regulation | Phosphorylation | MTOR | hsa2475 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Down-regulation | Expression | PIK3CA | hsa5290 | |
| In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
| Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0326 | |
| Result | Vinpocetine may be a potential candidate for sorafenib sensitization and HCC treatment, and our results may help to elucidate more effective therapeutic options for HCC patients with sorafenib resistance. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Enhanced anticancer activity by the combination of vinpocetine and sorafenib via PI3K/AKT/GSK-3β signaling axis in hepatocellular carcinoma cells. Anticancer Drugs. 2021 Aug 1;32(7):727-733. doi: 10.1097/CAD.0000000000001056. | Click |
